87 results on '"Shah, Urvi A"'
Search Results
2. Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies
3. CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
4. Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse population
5. Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups
6. Optimization of Plasma-activated Water and Validation of a Potential Surrogate for Salmonella for Future Egg Washing Processes
7. Whole-genome landscape of adult T-cell leukemia/lymphoma
8. Interventions and outcomes of patients with multiple myeloma receiving salvage treatment after BCMA-directed CAR T therapy
9. Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
10. Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma
11. MM-530 Interventions and Outcomes of Multiple Myeloma Patients Progressing after BCMA-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy
12. Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma
13. North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies
14. P09-002-23 Assessing Dietary Compliance of a Plant-Based Dietary Intervention in Patients With Precursor Plasma Cell Disorders - The Nutrition Prevention (NUTRIVENTION) Study
15. Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin
16. Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens
17. Low Intake of Fruits and Vegetables and High Intake of Processed Meats and Juices Are Associated with Risk of MGUS in the National Health and Nutrition Examination Survey (NHANES) Database
18. A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression
19. A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) Study
20. A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea
21. Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
22. Trends in Collection and Utilization of Autologous Hematopoietic Stem Cells (APBHC) Intended for Transplant in Patients with Multiple Myeloma
23. Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy
24. Microbial Changes in Response to a Plant-Based Diet and/or Supplements in SMM Patients: A National Multi-Arm Randomized Prospective Telehealth Study Via Healthtree: The Nutrition Prevention (NUTRIVENTION-2) Study
25. Allogeneic but Not Autologous Stem Cell Transplantation Improves Outcome in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma
26. Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma
27. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
28. Dietary Patterns Among Individuals with Plasma Cell Disorders Compared to the General US Population
29. North American Adult T-Cell Leukemia/Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist, CCR4-351
30. The Complex Structural Variant Chromothripsis Can be Defined on Targeted Sequencing Panels, Allowing Direct Clinical Translation in Order to Improve Multiple Myeloma Prognostication
31. Clinical Outcomes Associated with Del(17p) in Newly Diagnosed Multiple Myeloma Treated with Triplet and Daratumumab-Based Quadruplet Induction Regimens
32. Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy
33. P-486 Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
34. P-484 Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias
35. P-483 A whole foods plant-based weight loss intervention improves metabolic and immune biomarkers in MGUS/SMM patients as well as progression trajectory in a subset: the NUTRIVENTION trial
36. P-467 Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse national health and nutrition examination survey (NHANES) case-control study
37. P-354 Whole genome sequencing reveals significant genetic admixture in multiple myeloma patients, impacting assessment of etiology
38. P-166 Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
39. P-162 Adding Plinabulin to pegfilgrastim to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant for multiple myeloma
40. P-095 Evolving M-spike and risk of progression in smoldering multiple myeloma
41. P-089 Evaluating dynamic changes in the serum free light chain ratio and its effect on risk of progression in smoldering multiple myeloma
42. P-039 Vitamin D deficiency and clinical outcomes with chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma
43. P-038 Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
44. P-013 Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
45. P-007 Prognostic impact of corticosteroid and tocilizumab use on the efficacy of chimeric antigen receptor T-cell therapy for relapsed/ refractory multiple myeloma
46. OA-19 Comprehensive genomic characterization of response and resistance to daratumumab – based quadruplet induction in newly diagnosed multiple myeloma patients
47. OA-03 Bispecific T-cell engager response is driven by pre-treatment CD8+ effector memory cells and inhibited by TIGIT+ Tregs in relapsed/refractory multiple myeloma
48. MM-413 Early Mortality in Multiple Myeloma- a SEER Data Analysis
49. POSTER: MM-413 Early Mortality in Multiple Myeloma- a SEER Data Analysis
50. A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.